Dyslipidemia

A new analysis of 28 studies including more than 90k patients suggests 1-in-10 of these conditions is misdiagnosed, results in delays in treatment and potential harm.

Data presented at SCAI 2020 examining a novel cell therapy suggests it could help reduce angina in patients with non-obstructive coronary artery disease.

An analysis of the TWILIGHT trial presented at SCAI examines SYNERGY BP-EES in a high-risk patient population.

Results of the latest REDUCE-IT analysis shed light on the degree to which icosapent ethyl can reduce revascularization.

New research suggests consuming just one sugar-sweetened beverage per day increases risk of CVD by nearly 20% in women.

A new research letter has found declines in rural areas have not been as pronounced as declines in metropolitan areas.

The latest scientific statement from the association highlights the importance of healthy diet at a young age on preventing CVD later in life.

Discussing the impact of high-intensity statin therapy on patients with dry AMD with a study investigator from Byers Eye Institute.

A new analysis of two-year data from the FOURIER trial is shedding light on the impact of PCSK9 use for lowering LDL-C.

The latest scientific statement from the AHA addresses cardiovascular considerations before, during, and after pregnancy.

A new analysis of the FOURIER trial is diving into whether evolocumab use could slow or prevent progression of aortic stenosis.

A prespecified subanalysis revealed evolocumab use was associated with a significant reduction in risk of MI.

New research from investigators in Europe is shedding light on the impact of mental stress on risk of peripheral artery disease

If you can’t imagine starting the day without your cup o’ joe, you aren’t alone.  On average, American’s drink 3 cups of coffee every day–collectively that’s 400 million cups of coffee-- daily.  Given those kinds of numbers, it’s no wonder that the question of whether or not the coffee habit is beneficial or detrimental to patient health is one that generates a lot of interest- and there’s been plenty of studies devoted to it.  Here's a look at some of them.

New analysis of nationwide mortality statistics from the CDC is shedding light on an alarming trend among women in rural areas across the US.

Bhatt leads discussion on a new AHA statement regarding one of the most advancing fields of cardiovascular care.

A new Emory University-led study is shedding more light on the impact mental stress can have on cardiovascular health.

A discussion about a recent scientific statement outlining the treatment of coronary artery disease in type 2 diabetics from the AHA with statement co-author Deepak Bhatt, MD.

A new scientific statement from the AHA offers guidance to clinicians tasked with treating CAD in patients with type 2 diabetes.

A new retrospective analysis suggests CABG may be more appropriate for CAD patients with severely reduced left ventricular ejection fraction.

Results of an analysis of more than 20 randomized trials indicates women are at a greater risk of MACE and all-cause mortality than men following PCI.

How do e-cigarettes fit into the cardiovascular health paradigm? What more needs to be learned?

Discussing a REDUCE-IT substudy presented at ACC.20/WCC examining the impact of various EPA levels on outcomes seen in REDUCE-IT.

Results of the TICO study support use of ticagrelor monotherapy for patients with ACS requiring PCI with drug-eluting stents.

Results of a TWILIGHT subanalysis suggest ticagrelor monotherapy might cause less bleeding without increasing events in patients with requiring complex PCI.

A new subanalysis from the TWILIGHT trial found benefits of ticagrelor monotherapy remained consistent across both diabetics and nondiabetics.

Results of a pooled analysis of trials from the ORION program offer further insight into the effects of inclisiran on LDL-C in patients with atherosclerotic cardiovascular disease.

Marc Bonaca, MD, discusses the results of a subgroup analysis examining the impact of concomitant clopidogrel use in VOYAGER-PAD study.

A new ACC 2020 study shows the modifiable levels of CVD risk are distinguishable to long-term event possibility.

Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.